journal article
Open Access
Dec 01, 2022
A mechanistic physiologically based model to assess the effect of study design and modified physiology on formulation safe space for virtual bioequivalence of dermatological drug products
Abstract
Physiologically based pharmacokinetic (PBPK) models are widely accepted tools utilised to describe and predict drug pharmacokinetics (PK). This includes the use of dermal PBPK models at the regulatory level including virtual bioequivalence (VBE) studies. The current work considers the Topicort® Spray formulation, which contains 0.25% desoximetasone (DSM), as an example formulation. Quantitative formulation composition and in vitro permeation testing (IVPT) data were obtained from the public literature to develop a mechanistic model using the multi-phase, multi-layer (MPML) MechDermA IVPT module in the Simcyp Simulator. In vitro–in vivo extrapolation functionality was used to simulate in vivo PK for various scenarios and predict a ‘safe space’ for formulation bioequivalence using the VBE module. The potential effect of vasoconstriction, impaired barrier function, and various dosing scenarios on the formulation safe space was also assessed. The model predicted ‘safe space’ for formulation solubility suggesting that a 50% change in solubility may cause bio-in-equivalence, whereas viscosity could deviate by orders of magnitude and the formulation may still remain bioequivalent. Evaporation rate and fraction of volatile components showed some sensitivity, suggesting that large changes in the volume or composition of the volatile fraction could cause bio-in-equivalence. The tested dosing scenarios showed decreased sensitivity for all formulation parameters with a decreased dose. The relative formulation bioequivalence was insensitive to vasoconstriction, but the safe space became wider with decreased barrier function for all parameters, except viscosity that was unaffected.
Topics
No keywords indexed for this article. Browse by subject →
References
39
[1]
Alam "Research overview and regulatory experience on mechanistic modeling for generic dermatological drug products" (2021)
[2]
Alper "Measurement of epidermal thickness in a patient with psoriasis by computer-supported image analysis" Braz J. Med. Biol. Res. (2004) 10.1590/s0100-879x2004000100015
[3]
Anand "The use of physiologically based pharmacokinetic analyses—In biopharmaceutics applications -regulatory and industry perspectives" Pharm. Res. (2022) 10.1007/s11095-022-03280-4
[4]
Anissimov "Modelling dermal drug distribution after topical application in human" Pharm. Res. (2011) 10.1007/s11095-011-0437-2
[5]
Arora "Mechanistic modeling of in vitro skin permeation and extrapolation to in vivo for topically applied metronidazole drug products using a physiologically based pharmacokinetic model" Mol. Pharm. (2022) 10.1021/acs.molpharmaceut.2c00229
[6]
Bodenlenz "Open flow microperfusion as a dermal pharmacokinetic approach to evaluate topical bioequivalence" Clin. Pharmacokinet. (2017) 10.1007/s40262-016-0442-z
[7]
Braverman "Ultrastructure of the capillary loops in the dermal papillae of psoriasis" J. Invest. Dermatol. (1977) 10.1111/1523-1747.ep12485169
[8]
Brody "The ultrastructure of the epidermis in psoriasis vulgaris as revealed by electron microscopy. 7. The stratum corneum in hyperkeratosis" J. Ultrastruct. Res. (1963) 10.1016/s0022-5320(63)80058-1
[9]
Caspers "Method to quantify the in vivo skin penetration of topically applied materials based on confocal Raman spectroscopy" Transl. Biophot. (2019) 10.1002/tbio.201900004
[10]
Clarke "Predicting Depth Resolved Concentrations in the Dermis using PBPK modelling: Design, development and verification of the model with five drugs" AAPS PharmSci360 (2018)
[11]
Cordery "Topical bioavailability of diclofenac from locally-acting, dermatological formulations" Int. J. Pharm. (2017) 10.1016/j.ijpharm.2017.06.063
[12]
El Maghraby "Transdermal delivery of tadalafil. I. Effect of vehicles on skin permeation" Drug Dev. Ind. Pharm. (2009) 10.1080/03639040802360494
[13]
Fda (2015)
[14]
Garcia Ortiz "Are marketed topical metronidazole creams bioequivalent? Evaluation by in vivo microdialysis sampling and tape stripping methodology" Skin. Pharmacol. Physiol. (2011) 10.1159/000320151
[15]
Goldschmidt (1979)
[16]
Handler "Characterizing cutaneous drug delivery using open-flow microperfusion and mass spectrometry imaging" Mol. Pharm. (2021) 10.1021/acs.molpharmaceut.1c00285
[17]
Hansch (1995)
[18]
Incecayir "Assessment of topical bioequivalence using dermal microdialysis and tape stripping methods" Pharm. Res. (2011) 10.1007/s11095-011-0444-3
[19]
Kashibuchi "Three-dimensional analyses of individual corneocytes with atomic force microscope: Morphological changes related to age, location and to the pathologic skin conditions" Skin. Res. Technol. (2002) 10.1034/j.1600-0846.2002.00348.x
[20]
Kisak (2019)
[21]
Klemp "Cutaneous blood flow during white dermographism in patients with atopic dermatitis" J. Invest. Dermatol. (1982) 10.1111/1523-1747.ep12500070
[22]
Marks "Plasma and cutaneous drug levels after topical application of piroxicam gel: A study in healthy volunteers" Skin. Pharmacol. (1994) 10.1159/000211316
[23]
Moore (2022)
[24]
Nyfors "Cutaneous blood flow in psoriasis measured by 133-Xenonlearance" J. Invest. Dermatol. (1970) 10.1111/1523-1747.ep12259086
[25]
Oussedik "A randomized, double-blind, placebo-controlled study of the vasoconstrictor potency of topical 0.25% desoximetasone spray: A high to super high range of potency (class I to class II) corticosteroid formulation" J. Drugs Dermatol. (2017)
[26]
Patel "Multi-phase multi-layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin" (2022)
[27]
Pershing "Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products" J. Am. Acad. Dermatol. (2003) 10.1067/mjd.2003.175
[28]
pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures
Douglas E. V. Pires, Tom L. Blundell, David B. Ascher
Journal of Medicinal Chemistry
2015
10.1021/acs.jmedchem.5b00104
[29]
Polak (2019)
[30]
Rodgers "Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions" J. Pharm. Sci. (2006) 10.1002/jps.20502
[31]
Somayaji "An integrated biophysical model for predicting the clinical pharmacokinetics of transdermally delivered compounds" Eur. J. Pharm. Sci. (2021) 10.1016/j.ejps.2021.105924
[32]
Surber "Metamorphosis of vehicles: Mechanisms and opportunities" Curr. Probl. Dermatol. (2018) 10.1159/000489529
[33]
Taro Topicort (desoximetasone) topical spray label (2021)
[34]
Tsakalozou "Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1% CPT" CPT Pharmacometrics Syst. Pharmacol. (2021) 10.1002/psp4.12600
[35]
Undre "Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis" Br. J. Dermatol. (2009) 10.1111/j.1365-2133.2008.08974.x
[36]
White "The effect of washing on the thickness of the stratum corneum in normal and atopic individuals" Br. J. Dermatol. (1987) 10.1111/j.1365-2133.1987.tb05873.x
[37]
Wolberink "Cellular features of psoriatic skin: Imaging and quantification using in vivo reflectance confocal microscopy" Cytom. B Clin. Cytom. (2011) 10.1002/cyto.b.20575
[38]
Wu "Biopharmaceutics applications of physiologically based pharmacokinetic absorption modeling and simulation in regulatory submissions to the U.S. Food and drug administration for new drugs" Aaps J. (2021) 10.1208/s12248-021-00564-2
[39]
Zhang "Application of PBPK modeling and simulation for regulatory decision making and its impact on US prescribing information: An update on the 2018-2019 submissions to the US FDA's office of clinical Pharmacology" J. Clin. Pharmacol. (2020) 10.1002/jcph.1767
Metrics
15
Citations
39
References
Details
- Published
- Dec 01, 2022
- Vol/Issue
- 13
- License
- View
Authors
Cite This Article
J. F. Clarke, K. Thakur, S. Polak (2022). A mechanistic physiologically based model to assess the effect of study design and modified physiology on formulation safe space for virtual bioequivalence of dermatological drug products. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1007496
Related
You May Also Like
Toxic Mechanisms of Five Heavy Metals: Mercury, Lead, Chromium, Cadmium, and Arsenic
Mahdi Balali-Mood, Kobra Naseri · 2021
2,382 citations
The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety
Martins Ekor · 2014
2,316 citations
Advances and Challenges of Liposome Assisted Drug Delivery
Lisa Sercombe, Tejaswi Veerati · 2015
2,237 citations
Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning
Sigrid A. Langhans · 2018
1,331 citations
Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment
Runzhi Zhang, Xue Zhu · 2019
989 citations